Fig. 8

VE821 inhibits HCC by repressing the GRSF1/YY1 pathway. A GRSF1, YY1 and miR-30e-5p expression in MHCC-97H cells treated with different concentrations of VE821. B Representative images of subcutaneous tumors resected from mice in the VE821 or vehicle group. C CHX chase assay showing that VE821 impairs the protein stability of GRSF1. D VE821 shortened the YY1 mRNA half-life. E Proposed model for the effect of GRSF1 on hepatocarcinogenesis. GRSF1 facilitates HCC growth and metastasis by competing with miR-30e-5p for binding to the YY1 3`UTR 2663-2847, and YY1 feedback promotes GRSF1 expression by binding to GRSF1 promoters. VE821 may serve as a novel agent with potential for HCC treatment through inhibition of the GRSF1/YY1 axis. Values are the mean± SEM (n=3). *p<0.05, **p<0.01